Syndex Bio closed a $15.5 million seed round led by Arch Venture Partners to develop mcPCR, a methylation‑preserving PCR amplification technology. mcPCR uses engineered methyltransferases to copy 5‑methylcytosine onto complementary strands during thermal cycling, avoiding bisulfite conversion that destroys DNA and reduces assay sensitivity. The startup plans to apply mcPCR to liquid biopsy and epigenetic diagnostics where retaining methylation context boosts detection of rare epigenetic signatures in cell‑free DNA.